CytomX Therapeutics, Inc. (CTMX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CTMX currently has 218M outstanding shares. with limited dilution risk as only 33.8M additional shares (15.5%) are authorized for issuance. The company has significantly diluted shareholders by 221.85% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 217.7M shares outstanding |
220M | 34M |
| Mar 16, 2026 |
10-K filing | 170.2M shares outstanding |
170M | 81M |
| Nov 06, 2025 |
10-Q filing | 165.0M shares outstanding |
170M | 87M |
| Aug 07, 2025 |
S-3 filing: The company intends to offer and sell up to $250,000,000 in common stock, preferred stock, debt securities, warrants and units. |
87M | 160M |
| Aug 07, 2025 |
10-Q filing | 164.9M shares outstanding |
160M | 0 |
| May 12, 2025 |
10-Q filing | 87.1M shares outstanding |
87M | 49M |
| Mar 06, 2025 |
10-K filing | 84.4M shares outstanding |
84M | 52M |
| Nov 07, 2024 |
10-Q filing | 85.1M shares outstanding |
85M | 51M |
| Aug 09, 2024 |
S-3 filing: The company is filing an S-3 to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
78M | 58M |
| Aug 08, 2024 |
10-Q filing | 84.9M shares outstanding |
85M | 2M |
| May 08, 2024 |
10-Q filing | 82.0M shares outstanding |
82M | 4.9M |
| Mar 11, 2024 |
10-K filing | 73.8M shares outstanding |
74M | 13M |
| Nov 07, 2023 |
10-Q filing | 67.0M shares outstanding |
67M | 20M |
| Aug 16, 2023 |
S-3 filing: This is an S-3 filing for the resale of 25,961,539 shares of common stock by selling securityholders. |
67M | 20M |
| Aug 08, 2023 |
10-Q filing | 66.5M shares outstanding |
67M | 0 |
| May 09, 2023 |
10-Q filing | 66.2M shares outstanding |
66M | 0 |
| Mar 27, 2023 |
10-K filing | 65.7M shares outstanding |
66M | 0 |
| Nov 08, 2022 |
10-Q filing | 65.9M shares outstanding |
66M | 0 |
| Aug 04, 2022 |
10-Q filing | 65.5M shares outstanding |
66M | 0 |
| May 05, 2022 |
10-Q filing | 65.4M shares outstanding |
65M | 0 |
| Mar 01, 2022 |
10-K filing | 65.4M shares outstanding |
65M | 0 |
| Nov 04, 2021 |
10-Q filing | 65.2M shares outstanding |
65M | 0 |
| Aug 17, 2021 |
S-3/A filing: CytomX Therapeutics, Inc. may offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
65M | 0 |
| Aug 05, 2021 |
S-3 filing: The filing is for a shelf registration to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and/or debt securities from time to time in one or more offerings. |
61M | 0 |
| Aug 05, 2021 |
10-Q filing | 65.2M shares outstanding |
65M | 0 |
| May 06, 2021 |
10-Q filing | 61.0M shares outstanding |
61M | 0 |
| Feb 24, 2021 |
10-K filing | 64.8M shares outstanding |
65M | 0 |
| Nov 05, 2020 |
10-Q filing | 46.2M shares outstanding |
46M | 0 |
| Aug 06, 2020 |
10-Q filing | 46.2M shares outstanding |
46M | 0 |
| May 07, 2020 |
10-Q filing | 45.7M shares outstanding |
46M | 0 |
| Feb 27, 2020 |
10-K filing | 45.6M shares outstanding |
46M | 0 |